AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19303683
Drug: Continuous increase
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous increase in uric acid levels (1 mg/dL)
Trial: 12031560
Drug: 50-microg misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50-microg misoprostol tablet placed in the posterior vaginal fornix
Trial: 9440664
Drug: Glyburide 20
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide 20 mg
Trial: 2775607
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg DUP 996
Trial: 361155
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg eight-hourly plus phentolamine 20 mg three-hourly by mouth for three weeks
Trial: 27633773
Drug: Manipulated morphine-ADER-IMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulated morphine-ADER-IMT (60 mg, manipulated)
Trial: 27633773
Drug: Intact morphine-ADER-IMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact morphine-ADER-IMT (60 mg, intact)
Trial: 24910102
Drug: Ketamine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.3 mg/kg
Trial: 8092501
Drug: Morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.1 mg/kg
Trial: 23096008
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg L-theanine via capsules
Trial: 23096008
Drug: L-theanine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-theanine (both treatments)
Trial: 19735580
Drug: hLF1-11 (0.005,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hLF1-11 (0.005, 0.05, 0.5, 5 mg single and multiple intravenous doses)
Trial: 19735580
Drug: hLF1-11 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hLF1-11 (5 mg single intravenous dose)
Trial: 3428343
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml saline in the lumbar epidural interspace (n = 5)
Trial: 3428343
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml saline in the thoracic epidural interspace (n = 5)
Trial: 27798211
Drug: Atazanavir/cobicistat (300/150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/cobicistat (300/150 mg) + daclatasvir (30 mg) once daily
Trial: 27798211
Drug: Atazanavir/ritonavir (300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir (300/100 mg) + daclatasvir (30 mg) once daily
Trial: 26637210
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of mycophenolate mofetil (MMF) - 1.03 ± 0.19 g/day at 1 week
Trial: 21503807
Drug: Acetaminophen (APAP)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (APAP) 975 mg
Trial: 17036476
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of nylestriol for 3 months, 2 mg each time, twice each month; medroxyprogesterone added from the third month for 7 days, 6 mg each day.
Trial: 1304807
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg chloral hydrate with 25 mg hydroxyzine
Trial: 1304807
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg temazepam
Trial: 24776754
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) dosed per m2 BSA
Trial: 24776754
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) dosed per kg BW
Trial: 23169946
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens alone (0.625 mg/d)
Trial: 20130951
Drug: Cefepime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (2 g x 2/day)
Trial: 13680555
Drug: β-blockade treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blockade treatment
Trial: 1427414
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg aspirin/day
Trial: 28328548
Drug: TDF/FTC (once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF/FTC (once-weekly directly observed therapy)
Trial: 23085738
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg loading dose (LD) followed by 10 mg maintenance dose (MD) for 10 days
Trial: 25286173
Drug: β-lactam monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-lactam monotherapy
Trial: 21395645
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ABZ
Trial: 21395645
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ABZ + 1500 mg PZQ
Trial: 15565824
Drug: EC plus
RxNorm normalized name: Ivomec Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC plus filgrastim (480 microg or 300 microg daily or every other day, on day 8 through day 14, and 300 microg daily on days 8 and 12 of each chemotherapy course)
Trial: 10655529
Drug: Rice flour
RxNorm normalized name: Rice Flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice flour (50 g per liter of oral rehydration solution)
Trial: 10655529
Drug: High-amylose maize
RxNorm normalized name: hydroxypropyl distarch phosphate, high amylose corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-amylose maize starch (50 g per liter of oral rehydration solution)
Trial: 31806540
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg olaparib twice daily
Trial: 31806540
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg olaparib twice daily
Trial: 31806540
Drug: Olaparib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (both doses)
Trial: 18082500
Drug: Low-dose MCC-135
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose MCC-135
Trial: 18082500
Drug: High-dose MCC-135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose MCC-135
Trial: 12742838
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution (saline placebo)
Trial: 11044264
Drug: Micronutrient supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient supplementation with SP treatment
Trial: 11044264
Drug: Micronutrient supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient supplementation without SP treatment
Trial: 6539224
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg codeine phosphate
Trial: 1576052
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg propantheline bromide
Trial: 1576052
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide monohydrochloride
Trial: 21672343
Drug: Palonosetron 0.075
RxNorm normalized name: palonosetron 0.075 MG in 1.5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 0.075 mg
Trial: 23431958
Drug: Oral ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin 200 µg/kg body weight
Trial: 12577414
Drug: RT-GSP (Radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT-GSP (Radiotherapy combined with Ginseng polysaccharide injection)
Trial: 26336957
Drug: ezetimibe/simvastatin (10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/simvastatin (10/20 mg)
Trial: 26336957
Drug: atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin (10 mg, 20 mg)
Trial: 12882653
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor (PI) therapy
Trial: 1466216
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of parenteral morphine
Trial: 28007025
Drug: XELIRI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELIRI with or without bevacizumab (7.5 mg/kg on day 1), repeated every 3 weeks
Trial: 28007025
Drug: FOLFIRI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI with or without bevacizumab (5 mg/kg on day 1), repeated every 2 weeks
Trial: 21444695
Drug: Daptomycin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin (8 mg/kg of body weight)
Trial: 21444695
Drug: Control subjects
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control subjects (standard-of-care antibiotic)
Trial: 8543957
Drug: L-tryptophan
RxNorm normalized name: L-tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-tryptophan
Trial: 10199444
Drug: Tropisetron 5
RxNorm normalized name: tropisetron 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 5 mg intravenously followed by oral therapy for 5 days
Trial: 10199444
Drug: Tropisetron 5
RxNorm normalized name: tropisetron 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 5 mg intravenously plus dexamethasone before cisplatin and twice daily thereafter
Trial: 10199444
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide (2 mg/kg) combined with clemastine, dexamethasone, and lorazepam
Trial: 10199444
Drug: Tropisetron 5
RxNorm normalized name: tropisetron 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 5 mg intravenously plus dexamethasone
Trial: 8849290
Drug: Inpatient chemotherapy
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient chemotherapy (5-FU + CDDP)
Trial: 8849290
Drug: Oral UFT
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral UFT (400-600 mg/day) after chemotherapy
Trial: 1980218
Drug: Flumazenil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (10 ml, 0.1 mg/ml)
Trial: 1980218
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 ml vehicle alone)
Trial: 27523491
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg/0.05 mL)
Trial: 28335413
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (PG) - 20 mg placebo with half-dose antibiotics
Trial: 17766659
Drug: Pegaspargase (Oncaspar)
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegaspargase (Oncaspar) at a dose of 2,500 IU/m(2) administered i.m. on day 3 of the 4-week induction phase and on day 3 of each of two 8-week delayed intensification phases
Trial: 17766659
Drug: Native Escherichia
RxNorm normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native Escherichia coli asparaginase (Elspar) at a dose of 6,000 IU/m(2) administered i.m. three times weekly for nine doses during induction and for six doses during each delayed intensification phase
Trial: 9635312
Drug: Bur preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bur preparation with a 1/4-round bur in a low-speed handpiece and acid etching
Trial: 9635312
Drug: Conventional preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional preparation (pumicing and acid etching with 37% phosphoric acid)
Trial: 3123539
Drug: Oral cromolyn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cromolyn sodium (up to 40 mg/kg/day for 1 week)
Trial: 31264770
Drug: Unilateral strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral strength training with mirror therapy (MST)
Trial: 27914243
Drug: Bevacizumab-containing neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab-containing neoadjuvant therapy (BCP)
Trial: 24013512
Drug: 5 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 × 5 Gy irradiation followed by oxaliplatin-based chemotherapy
Trial: 2642790
Drug: Systemic antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotic treatment combined with topical application of antibiotics in the wound at the time of wound closure
Trial: 50611
Drug: SCHEDULE A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCHEDULE A (control): conventional one treatment per day regimen totalling 3,760 rads in 22‐23 days
Trial: 9601228
Drug: Myofunctional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofunctional therapy
Trial: 27913971
Drug: Placebo myofunctional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo myofunctional therapy
Trial: 16604967
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of contrast material (300 mgI/ml) only
Trial: 16604967
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of contrast material (350 mgI/ml) only
Trial: 25150116
Drug: Blueberry powder
RxNorm normalized name: Amino Acids/Biotin/Blueberry Powder Extract/Boron/Calcium/Cholecalciferol/Cyanocobalamin/Folic Acid/Magnesium/Pyridoxine 280 MCG-25 MG-500 MG-300 IU-125 MCG-1 MG-50 MG-10 MG Oral Tablet, Chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blueberry powder (BB), equivalent to 250 g berries daily for 6 weeks
Trial: 17305635
Drug: Topical cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporin
Trial: 10901509
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg daily)
Trial: 9809932
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) (0.625 mg of conjugated estrogen and 2.5 mg of medroxyprogesterone acetate daily)
Trial: 9809932
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HRT and Simvastatin
Trial: 8689742
Drug: Open flap/expanded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open flap/expanded polytetrafluoroethylene (e‐PTFE) membrane combination therapy
Trial: 8689742
Drug: Open flap
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open flap therapy alone
Trial: 23997371
Drug: Eszopiclone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eszopiclone (3 mg)
Trial: 16936810
Drug: 30% iron-saturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% iron-saturated bovine lactoferrin (bLf) (100 mg twice a day)
Trial: 16936810
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (pregnant women refusing treatment)
Trial: 23977198
Drug: DEP-CAF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEP-CAF (5 mg.kg(‐1) of caffeine intake 1 hour before the trial)
Trial: 17254579
Drug: Gonadotropin in
RxNorm normalized name: Choriogonadotropin intact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin in combination with metformin
Trial: 7957534
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) 100 mg
Trial: 7957534
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) 40 mg
Trial: 7957534
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) 400 mg
Trial: 7957534
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) 80 mg
Trial: 28099755
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (human NPH insulin/human regular insulin)
Trial: 25956891
Drug: Valacyclovir (VACV)
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valacyclovir (VACV) 2 g thrice daily for 90 days (n = 40)
Trial: 335789
Drug: Chlorpromazine (CPZ)
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (CPZ) 600 mg per day
Trial: 8951686
Drug: Cysteamine drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteamine drops (0.5% and 1.0%) administered preoperatively every half hour for two, four, six or eight hours
Trial: 1348805
Drug: Injection treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection treatment
Trial: 3908121
Drug: Labetalol 200-400
RxNorm normalized name: labetalol hydrochloride 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 200-400 mg twice daily
Trial: 3908121
Drug: Nifedipine and
RxNorm normalized name: nifedipine and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine and Labetalol in combination
Trial: 3908121
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Nifedipine and Labetalol)
Trial: 3908121
Drug: Labetalol alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol alone and in combination with Nifedipine
Trial: 19853687
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral anticoagulation therapy and clopidogrel 75 mg/d
Trial: 19853687
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (clopidogrel + oral anticoagulants + aspirin)
Trial: 11482539
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of multivitamins
Trial: 8227938
Drug: Spray to
RxNorm normalized name: DERMUSPRAY TOP AEROSOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray to eyes that were open
Trial: 27852348
Drug: Guided Self-Help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided Self-Help Cognitive Behavior Therapy (cGSH)
Trial: 10955773
Drug: 4‐HPR (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐HPR (200 mg once daily)
Trial: 8694306
Drug: Remifentanil small
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil small dose (0.5 micrograms.kg‐1.min‐1)
Trial: 8694306
Drug: Remifentanil large
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil large dose (1 microgram.kg‐1.min‐1)
Trial: 21095484
Drug: Generic atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic atorvastatin 20 mg/d
Trial: 21095484
Drug: Branded atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded atorvastatin 20 mg/d
Trial: 15997937
Drug: Periodontal ligament
RxNorm normalized name: human ligament preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal ligament injection with the Wand
Trial: 15997937
Drug: Traditional syringe
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional syringe injection
Trial: 9549398
Drug: Rest/postnitroglycerin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rest/postnitroglycerin (0.4 mg sublingually) technetium‐99m tetrofosmin SPET
Trial: 19615915
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% bolus (20 ml) before rib spreading (pre-RS)
Trial: 19615915
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% bolus (20 ml) after rib spreading (post-RS)
Trial: 7983238
Drug: Sustained-release codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release codeine (SRC) 150 mg every 12 hours for 5 doses
Trial: 7983238
Drug: Immediate-release codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate-release codeine phosphate (IRC) 60 mg (2 x 30 mg) every 4 hours for the first 3 doses, and 30 mg every 4 hours thereafter for 12 doses
Trial: 7983238
Drug: Sustained-release codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release codeine (SRC)
Trial: 7983238
Drug: Immediate-release codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate-release codeine phosphate (IRC)